Here's 5-stock ISA portfolio that could generate £1,000 per year in passive income
The dividend tax threshold has been coming down over the last few years. But for those who can avoid this by using an ISA, £20,000 can generate a lot of passive income.
With interest rates at 4.5%, it might be tempting to look for income outside the stock market. Over the long term, however, I think UK investors stand to do better with dividend shares.
Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.
I always look to invest in the best opportunities I can find, regardless of which exchange they're listed on. But with dividends, there are advantages to focusing on UK shares.
The most obvious is tax – distributions from companies outside the UK are subject to withholding taxes. In the case of the US, this is 30%.
That can be reduced to 15% with a W-8BEN form, but that's still enough to turn a 4% dividend yield into a 3.4% dividend yield. And investors have to factor this into their calculations.
If a US company is good (or cheap) enough, it could absolutely offset this cost. But UK shares have an immediate advantage for investors looking for passive income in an ISA.
Investing £20,000 to earn £1,000 per year implies a 5% dividend yield. And with UK shares prices where they are, I think that's highly achievable.
An example portfolio could look like this:
Stock
Dividend yield
Admiral
5.30%
Croda International
4.20%
Diageo
3.9%
Primary Health Properties
7.20%
Tesco
4.40%
Investing £4,000 into each of these stocks could generate £1,000 per year in dividends. And there's always the option to reinvest those dividends to earn more income in the future.
The stock with the highest dividend yield is Primary Health Properties (LSE:PHP). In general, I'm wary of stocks with unusually high yields, but this one is a rare exception.
Primary Health Properties is a FTSE 250-listed real estate investment trust (REIT). It makes money by owning and leasing GP surgeries throughout the UK (and a bit in Ireland).
As a REIT, the company has to distribute 90% of its rental income to investors in the form of dividends. And with most of its rent coming from the government, it's been very reliable.
One thing real estate companies want to avoid is vacancies, but demand for GP surgeries has generally been strong. And people living longer means this could well be a durable trend.
I think growth is likely to be steady, rather than spectacular. But with a dividend yield of 7.2% investors might well feel there's enough to generate a good return without big increases.
Given this, a natural question is why not just buy Primary Health Properties and forget about the other stocks? The answer is that – as with all shares – there are risks with the business.
The biggest potential issue is the fact the firm's debt is higher than its market value. So if it has to pay this off, the dividend per share could fall significantly.
Even if this happens, I don't think the stock will turn out to be a terrible investment. But it's why investors should consider it as part of a diversified portfolio, rather than by itself.
The post Here's 5-stock ISA portfolio that could generate £1,000 per year in passive income appeared first on The Motley Fool UK.
More reading
5 Stocks For Trying To Build Wealth After 50
One Top Growth Stock from the Motley Fool
Stephen Wright has positions in Diageo Plc. The Motley Fool UK has recommended Admiral Group Plc, Croda International Plc, Diageo Plc, Primary Health Properties Plc, and Tesco Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2025

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
3 UK Stocks Estimated To Be Trading Up To 46.9% Below Intrinsic Value
Amidst a challenging environment for the UK market, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, investors are keenly searching for opportunities that may be undervalued. In such conditions, identifying stocks trading below their intrinsic value can offer potential advantages by focusing on companies with strong fundamentals that are temporarily overlooked by the broader market. Name Current Price Fair Value (Est) Discount (Est) Vistry Group (LSE:VTY) £6.54 £11.88 44.9% Victrex (LSE:VCT) £8.07 £15.59 48.3% Van Elle Holdings (AIM:VANL) £0.385 £0.69 44.2% LSL Property Services (LSE:LSL) £2.99 £5.63 46.8% Informa (LSE:INF) £8.006 £14.50 44.8% Huddled Group (AIM:HUD) £0.0325 £0.06 45.6% Greatland Gold (AIM:GGP) £0.157 £0.3 46.9% Gooch & Housego (AIM:GHH) £5.94 £11.04 46.2% GlobalData (AIM:DATA) £1.725 £3.09 44.2% Entain (LSE:ENT) £7.538 £13.66 44.8% Click here to see the full list of 55 stocks from our Undervalued UK Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: Greatland Gold plc, along with its subsidiaries, is engaged in the exploration and development of precious and base metals in Australia, with a market cap of £2.08 billion. Operations: Greatland Gold plc focuses on the exploration and development of precious and base metals in Australia, but currently does not report any revenue segments. Estimated Discount To Fair Value: 46.9% Greatland Gold is trading significantly below its estimated fair value, presenting an opportunity for investors focused on cash flow valuation. Despite recent shareholder dilution, the company's revenue and earnings are forecast to grow substantially faster than the UK market. The upcoming Australian Securities Exchange cross-listing could enhance its financial flexibility and investor base. However, potential investors should consider the impact of large one-off items on earnings quality and a historically volatile share price. Our comprehensive growth report raises the possibility that Greatland Gold is poised for substantial financial growth. Click here to discover the nuances of Greatland Gold with our detailed financial health report. Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia, and it has a market cap of approximately £1.30 billion. Operations: Genus generates revenue from its Genus ABS segment, including operations in Asia, amounting to £311.10 million, and its Genus PIC segment, also inclusive of Asia, totaling £358 million. Estimated Discount To Fair Value: 13.8% Genus is trading at £19.76, below its estimated fair value of £22.92, suggesting it may be undervalued based on cash flows. The company's revenue is expected to grow faster than the UK market, with earnings projected to increase by 46.67% annually over the next three years as it moves toward profitability. Recent FDA approval for PRP gene edit in the U.S., alongside ongoing international regulatory progress, enhances Genus's growth prospects and potential market expansion opportunities. The growth report we've compiled suggests that Genus' future prospects could be on the up. Dive into the specifics of Genus here with our thorough financial health report. Overview: Vistry Group PLC, with a market cap of £2.13 billion, provides housing solutions in the United Kingdom through its subsidiaries. Operations: The company's revenue is primarily generated from its Home Builders segment, which focuses on residential and commercial projects, amounting to £3.78 billion. Estimated Discount To Fair Value: 44.9% Vistry Group, trading at £6.54, is significantly undervalued with a fair value estimate of £11.88. The company's earnings are expected to grow by 32.9% annually, outpacing the UK market's growth rate of 14.4%. Despite a decrease in net income from £215 million to £74.5 million last year, Vistry's forward order book remains robust at £4.6 billion, indicating strong future cash flows and potential for recovery in profit margins currently at 2%. According our earnings growth report, there's an indication that Vistry Group might be ready to expand. Get an in-depth perspective on Vistry Group's balance sheet by reading our health report here. Unlock our comprehensive list of 55 Undervalued UK Stocks Based On Cash Flows by clicking here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:GGP LSE:GNS and LSE:VTY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
37 minutes ago
- Bloomberg
KKR Raises Offer for Assura, Valuing Landlord at £1.7 Billion
A consortium led by KKR & Co has increased its bid in a takeover battle for Assura Plc, valuing the UK healthcare landlord at £1.7 billion ($2.3 billion). KKR and its co-bidder, Stonepeak Partners LP, sweetened their cash offer to an implied total value of 52.1 pence for each Assura share, inclusive of declared dividends, according to a statement on Wednesday. That compares with an implied total value of 51.7 pence put forward by rival Primary Health Properties Plc earlier.
Yahoo
an hour ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data